Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Revenue (2019 - 2023)

Benitec Biopharma has reported Revenue over the past 5 years, most recently at $7000.0 for Q2 2023.

  • Quarterly results put Revenue at $7000.0 for Q2 2023, changed N/A from a year ago — trailing twelve months through Mar 2024 was $7000.0 (down 89.71% YoY), and the annual figure for FY2023 was $75000.0, up 2.74%.
  • Revenue reached $7000.0 in Q2 2023 per BNTC's latest filing, down from $54000.0 in the prior quarter.
  • Across five years, Revenue topped out at $77000.0 in Q4 2019 and bottomed at -$35000.0 in Q2 2020.
  • Median Revenue over the past 5 years was $25000.0 (2021), compared with a mean of $23846.2.
  • The largest annual shift saw Revenue plummeted 98.7% in 2020 before it soared 4700.0% in 2022.
  • Over 5 years, Revenue stood at $77000.0 in 2019, then tumbled by 98.7% to $1000.0 in 2020, then surged by 2400.0% to $25000.0 in 2021, then plummeted by 44.0% to $14000.0 in 2022, then tumbled by 50.0% to $7000.0 in 2023.
  • Business Quant data shows Revenue for BNTC at $7000.0 in Q2 2023, $54000.0 in Q1 2023, and $14000.0 in Q4 2022.